EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders

Maria Luiza Góes Gurgel, Ana Luísa Carrijo Ferreira, Luisa da Costa Mello, Amanda Comandolli Caldato, Sofia Zaher do Canto, Pietra Brossi Camilotti, Manuela Ruela Folino Silva, Raissa Assalin Gomes, Beatriz Bomfim Wiltemburg, Giulia Spadone Perini, Manoela Rosa Bertipaglia, Rafaella Barcelos de Matos und 3 weitere

International Health Sciences Review · 10.11.2026 · 2 (6)

DOI: 10.70164/ihsr.v2i6.268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 10.11.2026. Verfasst von Maria Luiza Góes Gurgel und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe the pharmacological mechanisms, clinical efficacy, and safety of psilocybin- and MDMA-assisted therapies for depression and post-traumatic stress disorder (PTSD), while critically examining the methodological limitations of current evidence.

Methods

This narrative, non-systematic literature review was conducted between September and November 2026. PubMed/MEDLINE was searched for publications from January 2016 to November 2026. Randomized clinical trials, systematic reviews, meta-analyses, and studies addressing mechanisms of action and safety were considered. Twelve references were selected and qualitatively synthesized.

Results

Psilocybin demonstrated significant reductions in depressive symptoms, with a moderate pooled effect size (Hedges' g = 0.66). Evidence specifically concerning treatment-resistant depression remains limited. MDMA-assisted psychotherapy showed significant reductions in PTSD severity in two phase 3 trials, with favorable response and remission rates. Both interventions presented acceptable tolerability under controlled clinical conditions, although transient adverse effects were frequent. Serious adverse events were reported particularly among individuals with pre-existing neuropsychiatric conditions. Major limitations included difficulties with blinding, expectancy bias, uncertain long-term efficacy, and limited population diversity.

Conclusion

Psychedelic-assisted therapies represent promising investigational approaches in psychiatry. However, methodological limitations and safety uncertainties warrant clinical caution and further rigorous research before broader therapeutic implementation.

Zitieren

APA

Gurgel, M. L. G., Ferreira, A. L. C., Mello, L. D. C., Caldato, A. C., Canto, S. Z. D., Camilotti, P. B., Silva, M. R. F., Gomes, R. A., Wiltemburg, B. B., Perini, G. S., Bertipaglia, M. R., Matos, R. B. D., Orsi, E. S., Nacle, F. O., & Ribeiro, G. F. D. (2026). Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders. International Health Sciences Review, 2(6). https://doi.org/10.70164/ihsr.v2i6.268

Vancouver

Gurgel MLG, Ferreira ALC, Mello LDC, Caldato AC, Canto SZD, Camilotti PB, et al. Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders. International Health Sciences Review. 2026;2(6). doi:10.70164/ihsr.v2i6.268

BibTeX
@article{Gurgel2026,
  author = {Gurgel, Maria Luiza Góes and Ferreira, Ana Luísa Carrijo and Mello, Luisa da Costa and Caldato, Amanda Comandolli and Canto, Sofia Zaher do and Camilotti, Pietra Brossi and Silva, Manuela Ruela Folino and Gomes, Raissa Assalin and Wiltemburg, Beatriz Bomfim and Perini, Giulia Spadone and Bertipaglia, Manoela Rosa and Matos, Rafaella Barcelos de and Orsi, Enzo Seletti and Nacle, Fernanda Oliveira and Ribeiro, Gabriela Fernandes Daniel},
  title = {Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders},
  journal = {International Health Sciences Review},
  year = {2026},
  volume = {2},
  number = {6},
  doi = {10.70164/ihsr.v2i6.268}
}
Kostenlos starten →